Stephens & Co. Downgrades Evolent Health to Equal-Weight, Announces $16 Price Target
Stephens & Co. Downgrades Evolent Health to Equal-Weight, Announces $16 Price Target
Stephens & Co. 將 evolent health 評級下調至等權,宣佈目標價爲16美元
Stephens & Co. analyst Jeff Garro downgrades Evolent Health (NYSE:EVH) from Overweight to Equal-Weight and announces $16 price target.
史蒂芬斯分析師傑夫·加羅將 evolent health(紐交所:EVH)的評級從增持調降至持平,並公佈了16美元的目標價。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。